Aurobindo Pharma updates on US FDA inspection at Unit XI

Aurobindo Pharma Ltd's Unit XI, an API Non-antibiotic manufacturing facility situated at Pydibhimavaram, Srikakulam District, Andhra Pradesh was inspected by the United States Food and Drug Administration (USFDA) in February 2019 and issued a warning letter in June 2019 and this Unit was further inspected by USFDA from 25th July to 2nd August 2022 and issued a Form 483 with 3 observations.

Subsequent to the responses for the aforesaid observations, the company has received an Establishment Inspection Report (EIR) classifying the inspection as Voluntary Action Indicated (VAI) from the US FDA and with this, the inspection at the Unit XI is concluded.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 478.10 as compared to the previous close of Rs. 491.70. The total number of shares traded during the day was 142829 in over 3761 trades.

The stock hit an intraday high of Rs. 494.65 and intraday low of 475.80. The net turnover during the day was Rs. 69081465.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EIR Inspection USFDA UnitXI